A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody-Drug Conjugate (ADC), in Patients With Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) and Endometrial Cancers

Conditions

Corpus Uteri | Ovary

Phase I

Volunteers
Health Professionals

What is the purpose of this trial?

Phase 1 trial to study the safety, pharmacokinetics and preliminary efficacy of STRO-002 given intravenously every 3 weeks.

Gender
Female only

Find out more about who can participate in this trial

Trial with
Sutro Biopharma Inc.
Start Date
12/21/2021
End Date
08/31/2022

For more information about this study, contact:

Lisa Baker

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

Volunteer Now

Principal Investigator

Alessandro Santin, MD
Professor of Obstetrics, Gynecology, and Reproductive Sciences; Disease Aligned Research Team Leader, Gynecologic Oncology Program, Yale Cancer Center; Co-Chief, Section of Gynecologic Oncology

Sub-Investigators

Last Updated
12/22/2021
Study HIC
#2000030071

A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody-Drug Conjugate (ADC), in Patients With Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) and Endometrial Cancers

Conditions

Volunteers

Health Professionals

What is the purpose of this trial?

I'm interested in volunteering

Principal Investigator

Sub-Investigators

Contact Information